Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul-Aug;42(4):689-699.
doi: 10.1111/pde.15778. Epub 2025 May 13.

Management of Oral Mucositis in Pediatric Patients: A Practical Overview of Available Treatment

Carly Mulinda  1 , Neha Kinariwalla  2 , Amy R DeFelice  3 , Shantanu Lal  4 , Christine T Lauren  3   5
Affiliations
Review

Management of Oral Mucositis in Pediatric Patients: A Practical Overview of Available Treatment

Carly Mulinda et al. Pediatr Dermatol. 2025 Jul-Aug.

Abstract

Oral mucositis (OM) is an inflammatory condition associated with breakdown of the protective mucosal barrier. Clinically, it can range from mucosal erythema to painful ulcerations that can lead to malnutrition, secondary infection, and increased medical costs due to hospitalizations. Existing literature regarding OM primarily investigates antineoplastic-induced OM in the adult population; however, many non-oncologic disease processes can present with OM, including autoimmune and infectious conditions such as pemphigus vulgaris, recurrent aphthous stomatitis, oral lichen planus, and reactive infectious mucocutaneous eruption. Management of OM is largely palliative and can be grouped into four domains: pain control, oral decontamination, nutritional support, and palliation of dry mouth. This review aims to articulate the current topical management strategies for symptom relief and treatment of OM in children secondary to non-oncologic disease processes. Future studies are needed to strengthen the evidence base for interventions in children with refractory OM that is not caused by oncotherapy.

Keywords: antisepsis; anti‐inflammatory therapy; mucositis diseases/mechanisms; oral mucositis; pain control.

PubMed Disclaimer

References

    1. S. Elad, K. K. F. Cheng, R. V. Lalla, et al., “MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis Secondary to Cancer Therapy,” Cancer 126, no. 19 (2020): 4423–4431, https://doi.org/10.1002/cncr.33100.
    1. I. A. Hargitai, “Painful Oral Lesions,” Dental Clinics 62, no. 4 (2018): 597–609, https://doi.org/10.1016/j.cden.2018.06.002.
    1. R. M. D. Daniel, S. D. O. Jason, and S. J. Jeffrey, “BET 2: Does Topical Lidocaine Improve Oral Intake in Children With Painful Mouth Ulcers?,” Emergency Medicine Journal 37, no. 2 (2020): 113–114, https://doi.org/10.1136/emermed‐2019‐209390.3.
    1. C. H. L. Hong, L. A. Gueiros, J. S. Fulton, et al., “Systematic Review of Basic Oral Care for the Management of Oral Mucositis in Cancer Patients and Clinical Practice Guidelines,” Support Care Cancer 27, no. 10 (2019): 3949–3967, https://doi.org/10.1007/s00520‐019‐04848‐4.
    1. W. Miranda‐Silva, W. Gomes‐Silva, Y. Zadik, et al., “MASCC/ISOO Clinical Practice Guidelines for the Management of Mucositis: Sub‐Analysis of Current Interventions for the Management of Oral Mucositis in Pediatric Cancer Patients,” Support Care Cancer 29, no. 7 (2021): 3539–3562, https://doi.org/10.1007/s00520‐020‐05803‐4.

LinkOut - more resources